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PRP aggregometryAbstract Brahimi et al. in this journal formed a hypothesis that ‘‘the platelet count is underesti-
mated, by an automated cell counter, each time platelet aggregates are present in the sample tube.’’
The addition of a platelet agonist to a stimulated sample tube will lead to the formation of platelet
aggregates and hence to a drop in the platelet count. In the case of a hereditary platelet dysfunction,
platelet aggregates cannot be formed upon addition of a platelet agonist and the platelet count will
remain unchanged. The authors propose a hypothesis to develop ‘‘a more accessible screening tech-
nique for these hereditary platelet dysfunctions.’’ In our reply, we critically evaluate this screening
method and focus on the importance of the differences between impedance aggregometry in whole
blood versus aggregometry in platelet-rich plasma.
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22 I. Skornova et al.Dear sir,
We read with great interest the article by Brahimi et al. that
was recently published in this journal [1].
Brahimi et al. hypothesise that ‘‘the platelet count is
underestimated, by an automated cell counter, each time
platelet aggregates are present in the sample tube.’’ The addi-
tion of a platelet agonist to a stimulated sample tube will lead
to the formation of platelet aggregates and hence to a drop of
the platelet count. In the case of a hereditary platelet dys-
function, platelet aggregates cannot be formed upon addition
of a platelet agonist and the platelet count will remain un-
changed. The authors propose a hypothesis to develop ‘‘a
more accessible screening technique for these hereditary
platelet dysfunctions’’ [1].
The mentioned method was tested at our haematology
laboratory in the blood samples taken from patients without
thrombopathy. For analysis, adenosine diphosphate (ADP)
and ristocetin were used as inducers. The samples were col-
lected into tubes containing ethylenediaminetetraacetic acid
(EDTA) or citrate, because it is important that for aggre-
gometry, the blood samples must be drawn into evacuated
citrate tubes, while the haematology cell counters are cali-
brated for blood to be drawn to EDTA. Each sample was
stirred and analysed on the haematology cell counter DxH
800 (Beckman Coulter, Pasadena, CA, USA). After adding
the inducer into citrated blood samples, the results showed
an abnormal drop in the platelet count from a normal range
to minimal values of approximately 2–10 · 109/l. This result
could be consistent with the hypothesis of Brahimi et al. [1].
However, because of the low number of tested samples, we
were not able to standardise the method. The sample of a
patient with thrombopathy was not provided; therefore, no
quality control was carried out. Moreover, it is necessary
to stress that the aggregation is accelerated at 37 C, upon
rapid stirring, upon high concentrations of ADP and at a
high platelet concentration; a decrease in any of these condi-
tions slows down the process. It is also important to con-
sider the interference of the cells.
Finally, the hypothesis requires a difﬁcult standardisation
of methodology by fulﬁlling the conditions necessary for plate-
let aggregation. At present, it is not possible to use it in
practice.Overview BoxFirst Question: What do we already know about the
subject?
A summary of our knowledge about congenital thromb-
opathies and possibilities of their diagnostics is concisely
described in paper byBrahimi et al., published in this jour-
nal (J Med Hypotheses and Ideas 2013;7:11–4).
Second Question: What does your proposed theory add
to the current knowledge available, and what beneﬁts
does it have?
The authors suggest a simple and accessible screening
method for the detection of congenital thrombopathies
using only a haematology counter and some reagents.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
Similarly, as was stressed in the article by Brahimi et al.,
there is a lot of work to be done in comparative clinical
studies with normal subjects and patients with thromb-
opathies for the standardisation of the proposed
method and before its use in routine clinical practice.Conﬂict of interest
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